Business
Voyageur Pharmaceuticals Publishes White Paper, SmoothX: A Promising New Positive Oral Contrast Agent That Enhances Patient Satisfaction and Diagnostic Excellence in CT Imaging
(TheNewswire) Calgary, Canada – TheNewswire - June 12, 2023 - Voyageur P...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Publishes White Paper, SmoothX: A Promising New Positive Oral Contrast Agent That Enhances Patient Satisfaction and Diagnostic Excellence in CT Imaging\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary, Canada –\n \n \n TheNewswire\n-\n \n \n June 12, 2023 -\n \n \n Voyageur Pharmaceuticals Ltd\n \n \n . (\n \n \n TSXV:VM\n \n \n ) (\n \n \n USA\n \n \n : VYYRF) (\"Voyageur\" or\nthe \"Corporation\"), a provider of innovative medical imaging\nsolutions, is pleased to announce the release of the white paper\ntitled \"SmoothX: A Promising New Positive Oral Contrast Agent for\nCT.\" Authored by Alec J. Megibow, MD, MPH, FACR, the white paper\nhighlights the remarkable imaging properties of Voyageur's product,\nSmoothX™, emphasising its potential to optimize abdominal CT\nexaminations and maximize patient satisfaction.\n \n \n \n \n Oral contrast agents have long been vital in elevating\ndiagnostic accuracy and effectiveness in medical imaging procedures.\nWith the introduction of SmoothX, Voyageur is offering a positive oral\ncontrast agent that not only enhances diagnostic outcomes but also\nprovides a pleasant taste, enhancing patient satisfaction.\n \n \n \n \n In a recent blinded study comparing SmoothX with the\nestablished oral contrast agent Readi-CAT2, Voyageur conducted a\ndetailed evaluation, demonstrating that SmoothX exhibited nearly\nidentical diagnostic imaging properties. This finding establishes\nSmoothX as a reliable alternative that maintains the uncompromising\nstandards of image quality required for precise diagnosis.\n \n \n \n \n Of notable importance is the taste test study conducted\nalongside the clinical evaluation. The results revealed a remarkable\npreference for the palatable flavor of SmoothX among the majority of\nthe participants compared to Readi-CAT2. This preference for SmoothX's\ntaste has the potential to translate into heightened patient\nsatisfaction and increased compliance during abdominal CT\nexaminations.\n \n \n \n \n Voyageur extends heartfelt appreciation to the\ndedicated team at Canada Diagnostic Centre in Calgary for their\ninvaluable participation in this study. Under the exceptional\nleadership of Jay Zelazo, MD, FRCPC, Director of CT, along with Jordan\nMuth,\n \n \n M...